US 12,268,803 B2
Blood purifier
Teruhiko Oishi, Tokyo (JP); Yusuke Tokimizu, Tokyo (JP); Keitaro Matsuyama, Tokyo (JP); and Naoki Morita, Tokyo (JP)
Assigned to ASAHI KASEI MEDICAL CO., LTD., Tokyo (JP)
Appl. No. 17/426,841
Filed by Asahi Kasei Medical Co., Ltd., Tokyo (JP)
PCT Filed Mar. 27, 2020, PCT No. PCT/JP2020/014376
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/203923, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 2019-068818 (JP), filed on Mar. 29, 2019; and application No. 2020-004699 (JP), filed on Jan. 15, 2020.
Prior Publication US 2022/0111133 A1, Apr. 14, 2022
Int. Cl. A61M 1/36 (2006.01); B01J 20/06 (2006.01); B01J 20/26 (2006.01); B01J 20/28 (2006.01); B01J 20/285 (2006.01); B01J 20/32 (2006.01)
CPC A61M 1/3633 (2013.01) [A61M 1/361 (2014.02); B01J 20/06 (2013.01); B01J 20/261 (2013.01); B01J 20/262 (2013.01); B01J 20/28016 (2013.01); B01J 20/28071 (2013.01); B01J 20/28085 (2013.01); B01J 20/285 (2013.01); B01J 20/327 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A blood purifier having a body vessel and a porous formed article placed in the body vessel, wherein:
the porous formed article comprises a hydrophobic polymer and a hydrophilic polymer, the porous formed article has a low-melting point water content of 0.12 g or larger and 2.00 g or smaller per 1 g dry weight of the porous formed article, and the porous formed article has a contact-induced change rate of 0% or more and 0.2% or less;
a ratio L/D of length L in a longitudinal direction to equivalent circle diameter D at a cross section in a shorter direction of a region occupied by the porous formed article in the body vessel is 1.00 or more and 2.30 or less, wherein the equivalent circle diameter D is calculated according to a following expression (1):
D=2√V/L/3.14)  (1)
wherein V represents an apparent volume of the region occupied by the porous formed article in the body vessel; and
the blood purifier has a pressure loss of less than 13 kPa before blood processing and the blood purifier has a pressure loss of less than 13 kPa after blood processing when an aqueous polyvinylpyrrolidone solution having a viscosity of 3.75 mPa·s or higher and 3.85 mPa·s or lower is flowed in the blood purifier at a passing rate of 400 mL/min.